M. Weiss

KYM‐001, A FIRST‐IN‐CLASS ORAL IRAK4 PROTEIN DEGRADER, INDUCES TUMOR REGRESSION IN XENOGRAFT MODELS OF MYD88‐MUTANT ABC DLBCL ALONE AND IN COMBINATION WITH BTK INHIBITION

S. Rusin, D. Vigil, A. Mcdonald, 2019, Hematological Oncology.

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

A. Mcdonald, K. Sharma, Rahul Karnik, 2022, Blood.

Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders

R. Birge, D. Vigil, K. Sharma, 2023, Frontiers in immunology.

Abstract 3934: KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)

Bradley E. Enerson, K. Sharma, Rahul Karnik, 2022, Cancer Research.

Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of Irakimids and BCL2 Inhibition

J. Chaudhuri, A. Mcdonald, J. Gollob, 2022, Blood.

Abstract LB118: Mechanisms underlying synergistic activity in MYD88MTDLBCL of KT-413, a targeted degrader of IRAK4 and IMiD substrate

S. Rusin, A. Mcdonald, K. Sharma, 2021, Experimental and Molecular Therapeutics.